emjreviews.com1d
Prioritising Patients and Planet: Advocating for Change in Respiratory Care
Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...
emjreviews.com1d
Bronchiectasis Exacerbations: Are We Doing Everything We Can?
The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by ...
PharmiWeb15h
Global Progressive Fibrosing Interstitial Lung Disease Market Projected to Reach USD 8654.1 Million by 2033 at a 6.2% of CAGR
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...
How ‘green’ inhalers could evade Biden’s drug pricing legacy
The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...
Zawya4d
More than 300 regional experts gather in Cairo for Boehringer Ingelheim’s Forums
Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...
pharmaphorum8d
Pharma gets social: Boehringer ‘Digital Opinion Leader’ Twitter collaboration is a first
This month, Daniel Ghinn explores the digital and social media strategy of pharma company, Boehringer Ingelheim, during the European Respiratory Society congress on 9th September. In particular ...
Zealand, Boehringer win FDA breakthrough status to treat fatty liver
Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...
Pharmaceutical Technology9d
Boehringer partners WHO Foundation to advance healthcare access
Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...